

FOI 3748

20th May 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of January 2026 and the end of March 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organisation.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Response:

CURRENT PATIENTS AS OF 30/04/26

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	0
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	162
1.4 Lebrikizumab (Ebglyss)	<5
1.5 Mepolizumab (Nucala)	0
1.6 Omalizumab (Xolair)	<5
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Response:

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)	0	0	0
2.2 Depemokimab (Exdensur)	0	0	0
2.3 Dupilumab (Dupixent)	0	0	0
2.4 Mepolizumab (Nucala)	0	0	0
2.5 Omalizumab (Xolair)	0	0	0
2.6 Reslizumab (Cinqaero)	0	0	0
2.7 Tezepelumab (Tezspire)	0	0	0

Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Response:

CURRENT PATIENTS AS OF 30/04/26

Name of medicine	Number of patients with Atopic Dermatitis
3.1 Dupilumab (Dupixent)	162
3.2 Lebrikizumab (Ebglyss)	<5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Response:

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)	0	0	0
4.2 Depemokimab (Exdensur)	0	0	0
4.3 Dupilumab (Dupixent)	0	162	0
4.4 Lebrikizumab (Ebglyss)	0	<5	0
4.5 Mepolizumab (Nucala)	0	0	0
4.6 Omalizumab (Xolair)	0	<5	0
4.7 Reslizumab (Cinqaero)	0	0	0
4.8 Tezepelumab (Tezspire)	0	0	0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Email: foi.team@southerntrust.hscni.net